You will be shown biomedical passages and your task is to the answer the provided question. Provide a concise and accurate response and do not include any additional text in the response other than the answer.

Question: Sclerostin regulates what process?

Context: Sclerostin is a soluble antagonist of Wnt/β-catenin signaling secreted primarily by osteocytes. Current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
The osteocyte product sclerostin is emerging as an important paracrine regulator of bone mass.
Sclerostin is a secreted inhibitor of Wnt signaling and plays an essential role in the regulation of bone mass.
Sclerostin secreted by osteocytes is mechanosensory and important in bone remodeling.
Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss.
Sclerostin regulates bone formation by inhibiting Wnt pathway signaling.
Sclerostin, an osteocyte-expressed negative regulator of bone formation, is one of the inhibitors of Wnt signaling that is a critical pathway in the correct process of osteoblast differentiation.
Sclerostin, a secreted glycoprotein, regulates osteoblast function.
Sclerostin regulates bone formation by inhibiting Wnt/β-catenin signaling.
We suggest that sclerostin negatively regulates the formation of bone by repressing the differentiation and/or function of osteoblasts induced by BMPs.
Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss.
Since sclerostin expression is confined to the bone-resorbing osteoclast, it provides a mechanism whereby bone apposition is inhibited in the vicinity of resorption.
Sclerostin regulates bone formation by inhibiting Wnt/β-catenin signaling.
Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
The secreted glycoprotein, sclerostin alters bone formation.
Sclerostin, encoded by the sost gene, and a product of the osteocyte, is a negative regulator of bone formation.
Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover, and it plays a role in cardiovascular calcification processes.
Sclerostin plays a major role in regulating skeletal bone mass, but its effects in articular cartilage are not known.
Sclerostin is a key negative regulator of bone formation
Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and osteoblast differentiation
In humans, the SOST gene encodes sclerostin, an inhibitor of bone growth and remodeling, which also negatively regulates the bone repair process.
The glycoprotein sclerostin (Scl; 22 kDa), which is involved in bone metabolism,
bone metabolism